Nanochip Technology for B-Cell Lymphoma

Overseen by Beth Christian, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Recruiting

Sponsor: Ohio State University Comprehensive Cancer Center

No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial uses a special tiny chip to monitor treatment response and detect relapse in patients with diffuse large B-cell lymphoma by checking their blood for specific genetic markers. Rituximab has been a key component in treating diffuse large B-cell lymphoma.

Research Team

Beth Christian, MD

Principal Investigator

Ohio State University Comprehensive Cancer Center

Eligibility Criteria

This trial is for people with a specific blood cancer called diffuse large B-cell lymphoma (DLBCL) who haven't been treated before. Participants must plan to get all their care at Ohio State University, aim for a cure with treatment, and go through 6 cycles of chemotherapy. They also need to be able to give consent.

Inclusion Criteria

You must plan to receive all treatment and follow-up care at Ohio State University (OSU).

I have a specific type of untreated lymphoma.

I am undergoing treatment aimed at curing my condition.

Treatment Details

Interventions

• Molecular Nanotechnology (Other)

Trial Overview The study is testing nanochip technology (ILN biochip) to see how well it can monitor the effectiveness of treatments in real-time and detect any return of the disease in patients with DLBCL. Researchers are looking for genetic markers that could predict treatment outcomes.

Participant Groups

Group I: Diagnostic (ILN biochip testing) Experimental Treatment 1 Intervention

Participants' blood samples undergo ILN biochip testing at diagnosis, before and after every course of chemotherapy, every 3 months for 2 years, and at relapse.

Who Is Running the Clinical Trial?

Ohio State University Comprehensive Cancer Center

Lead Sponsor

Trials

350

Recruited

295,000+

Dr. David Cohn

Ohio State University Comprehensive Cancer Center

Interim Chief Executive Officer since 2022

MD, MBA

Dr. David Cohn

Ohio State University Comprehensive Cancer Center

Chief Medical Officer since 2018

MD